FinEdge Labs
B

BIIB

BIIBUnverified
28 segments tracked|10 years of data|Annual (10-K)
Total Revenue
$17.0B0.7%
FY2025
Operating Segments
28
Active segments
Blended Margin
0.0%
Operating margin
Highest Margin
0.0%
MSProduct Revenues
Segment Shift

MSProduct Revenues has grown from 0.0% to 23.8% of total revenue since FY2014, with 0.0% operating margins. Meanwhile, Alzheimers Collaboration is the fastest growing at +196.7% YoY.

Segment Revenue Over Time

Revenue Mix

Segment Breakdown — FY2025

SegmentRevenueOp. IncomeMargin% of TotalYoY
MSProduct Revenues$4.0B$00.0%23.8%-7.1%
Revenuesfromanticd20therapeuticprograms$1.9B$00.0%11.0%+6.3%
SPINRAZA$1.5B$00.0%9.1%-1.7%
Fumarate$1.4B$00.0%8.4%-10.6%
Royalty Attributed To OCREVUS$1.4B$00.0%8.3%+5.6%
Interferon$946M$00.0%5.6%-2.3%
VUMERITY$747M$00.0%4.4%+18.9%
Biosimilars$729M$00.0%4.3%-8.1%
AVONEX$696M$00.0%4.1%-1.7%
TECFIDERA$680M$00.0%4.0%-29.7%
Contract Manufacturing And Other Revenue$679M$00.0%4.0%+14.7%
SKYCLARYS$521M$00.0%3.1%+36.1%
BENEPALI$453M$00.0%2.7%-5.4%
PLEGRIDY$250M$00.0%1.5%-4.0%
Other$197M$00.0%1.2%+139.0%
ZURZUVAE$195M$00.0%1.1%+170.2%
IMRALDI$190M$00.0%1.1%-10.7%
Alzheimers Collaboration$178M$00.0%1.0%+196.7%
QALSODY$87M$00.0%0.5%+168.2%
Royalty$54M$00.0%0.3%-11.6%
FLIXABI$53M$00.0%0.3%-16.8%
BYOOVIZ$32M$00.0%0.2%-11.5%
FUMADERMAnd ADUHELM$2M$00.0%0.0%-79.6%
FAMPYRA$1M$00.0%0.0%-98.0%
TOFIDENCE$700,000$00.0%0.0%-36.4%
Clinical Inventory$0$00.0%0.0%+0.0%

Want more? Unlock the full analysis.

Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.

Get Started Free